New hope for aggressive blood cancer: drug combo trial opens

NCT ID NCT06043674

Recruiting now Disease control Sponsor: Christine Ryan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called glofitamab, alone or with other medicines, in people whose chronic lymphocytic leukemia (CLL) has turned into a more aggressive cancer called Richter's transformation. About 70 adults will receive treatment to see if the cancer shrinks or disappears. The goal is to find better options for this hard-to-treat condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA RICHTER'S TRANSFORMATION

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
The Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
The University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States
Winship Cancer Institute at Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.